Drug industry stakeholders are on edge as the Biden administration gears up to tout its success in negotiating the first tranche of Medicare Part D drug prices Thursday (Aug. 15), with analysts watching to see how officials frame the decreases without divulging confidential data and whether they will also unveil new formulary policies. An industry expert speculates the decision to make the announcement in Maryland, just days prior to the Democratic National Convention, is aimed at boosting Democrats’ chances in...